Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

Takeda

Takeda is exploring the potential of ‘digital biomarkers’ to help develop new mental health treatments, with a particular focus on schizophrenia and treatment-resistant depression.

The firm is collaborating with Mindstrong Health, whose digital phenotyping platform continuously measures brain function from passively collected smartphone data.

Emiliangelo Ratti, head of Takeda’s Neuroscience Therapeutic Area Unit, said: "Mental health disorders are complex, multifaceted conditions, and drug development in this area of unmet need is slow to progress.

"This partnership with Mindstrong Health exemplifies Takeda's motivation to engage in digital technologies to improve the clinical assessment of patients with mental health conditions who lack adequate treatment options."

Dr Paul Dagum, founder and CEO of Mindstrong Health, added: "Takeda shares our goal of using innovative technology to gain insights that will improve outcomes for people living with mental health conditions.

"We are pleased to partner with them to implement digital technology in the clinical development of novel assets and, hopefully, allow for faster delivery of meaningful therapies to patients."

The companies hope that by joining forces they will be able to develop novel therapeutic interventions by applying digital biomarkers to stratify mental health conditions and predict remission.

6th March 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...